Try our mobile app

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

Bristol-Myers Squibb Company is a global biopharmaceutical company. The Company develops, licenses, manufactures, markets, and sells pharmaceutical and nutritional products. Bristol-Myers Squibb products and experimental therapies address cancer, heart disease, HIV and AIDS, diabetes, rheumatoid arthritis, hepatitis, organ transplant rejection, and psychiatric disorders.
Website: bms.com


  • Good financial results growth rate 44.3% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (-0.9%)
  • Dividend yield for the last twelve months 4.8%
  • Free cash flow yield 8.0% (LTM)
  • Share price is 29.1% higher than minimum and 35.1% lower than maximum for the last 3 years
  • The company is undervalued by EV / LTM EBITDA multiple compared to target level (17.6x vs
    )
  • Fundamental value created in LTM (estimate)

Key Financials (Download financials)

Ticker: BMY
Share price, USD:  (+1.0%)51.1934
year average price 50.62  


year start price 56.65 2024-12-11

max close price 63.11 2025-03-10

min close price 42.60 2025-10-29

current price 51.24 2025-12-10
Common stocks: 2 111 517 922

Dividend Yield:  4.8%
FCF Yield LTM: 8.0%
EV / LTM EBITDA: 17.6x
EV / EBITDA annualized: 11.3x
Last revenue growth (y/y):  +2.8%
Last growth of EBITDA (y/y):  +85.8%
Historical revenue growth:  +1.0%
Historical growth of EBITDA:  -2.8%
Target EV / EBITDA (hist percentile):
Express share price potential:
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 108 096
Net Debt ($m): 33 300
EV (Enterprise Value): 141 396
EBITDA LTM ($m): 8 033
EV / LTM EBITDA: 17.6x
Price to Book: 5.8x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-12-10247wallst.com

5 Blue Chip Stocks to Buy Now That Pay Reliable 4%+ Dividends

2025-12-04seekingalpha.com

Bristol-Myers Squibb Company (BMY) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

2025-12-04zacks.com

BMY Gains on News of Continuation of Alzheimer's Disease Study

2025-12-03marketwatch.com

A delayed clinical trial actually boosted Bristol Myers Squibb's stock. Here's why.

2025-12-01reuters.com

Bristol Myers must face $6.7 billion lawsuit over delayed cancer drug, US judge rules

2025-12-01zacks.com

Here's Why Bristol Myers Squibb (BMY) is a Strong Value Stock

2025-12-01forbes.com

What Is Happening With BMY Stock?

2025-11-30fool.com

2 Undervalued, High-Quality Companies to Buy Now and Hold Forever

2025-11-30fool.com

2 Top Dividend Stocks to Buy and Hold

2025-11-29fool.com

Should You Buy Bristol Myers Stock for Its 5.4%-Yielding Dividend?
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data